Noradrenalina Altan (Noradrenaline Tartrate)

Noradrenaline is employed as a potent vasopressor in the management of critical‑care circulatory failure.

• Septic shock: restores arterial pressure when fluid resuscitation is insufficient, supporting organ perfusion.
• Cardiogenic shock: increases systemic vascular resistance to improve coronary perfusion and cardiac output.
• Cardiac arrest: administered during advanced life support to maintain coronary and cerebral blood flow.

• Noradrenaline tartrate exerts its pharmacologic effect primarily by stimulating α1‑adrenergic receptors on vascular smooth muscle, causing potent vasoconstriction and elevation of systemic vascular resistance. It also activates β1‑adrenergic receptors in the heart, modestly increasing heart rate and myocardial contractility, which together raise arterial pressure and improve perfusion during acute hypotensive states.

Noradrenaline infusion may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Tachycardia: increased heart rate due to β1 stimulation.
• Hypertension: excessive rise in blood pressure.
• Headache: vascular tension leading to pain.
• Anxiety or restlessness: central nervous system stimulation.
• Peripheral ischemia: reduced blood flow to extremities.
• Arrhythmia: irregular heart rhythm.

Serious or Rare Side Effects

• Myocardial ischemia: reduced coronary perfusion causing chest pain.
• Severe hypertension: risk of stroke or organ damage.
• Tissue necrosis at infusion site: due to extravasation.
• Ventricular tachyarrhythmias: life‑threatening heart rhythm disturbances.
• Pulmonary edema: fluid accumulation in lungs.

Use of Noradrenalina Altan requires careful monitoring and adherence to safety measures in critical care environments.

• Cardiovascular monitoring: continuous blood pressure and heart‑rate observation is essential.
• Dose titration: adjust infusion rate to achieve target mean arterial pressure.
• Renal or hepatic impairment: start with lower rates and monitor organ function.
• Concomitant MAO inhibitors: avoid due to risk of hypertensive crisis.
• Extravasation risk: ensure secure intravenous access and inspect site regularly.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenaline may interact with several medications, altering its pressor effect or increasing adverse risk.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors: can precipitate severe hypertension.
• Tricyclic antidepressants: additive vasoconstrictive effect may cause dangerous pressure spikes.
• Beta‑blockers: may blunt therapeutic response to noradrenaline.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: may enhance hypotensive episodes when discontinued.
• Calcium channel blockers: combined cardiovascular effects require observation.
• Diuretics: alterations in intravascular volume can affect dosing requirements.